Pfenex Eyes Teriparatide Launch Late Next Year As It Submits FDA Application
Executive Summary
Having moved recently its projected launch date for its follow-on teriparatide proudct, US-based Pfenex has settled on the fourth quarter of next year for potential market entry, with a commercialisation partner secured and a legal strategy at hand.